FDA Brief

Warning letters Drugs

FDA warning letter to

LCC Ltd.

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

What happened

FDA reviewed records LCC Ltd. submitted after FDA's March 3, 2023 request for records; there was no inspection. FDA found the firm did not test each shipment and lot of high-risk components such as glycerin and propylene glycol for identity, including limits for diethylene glycol (DEG) and ethylene glycol (EG) contamination, and that its quality unit did not adequately approve or reject components. FDA placed the firm on Import Alert 66-40 on May 3, 2023.

What FDA found

  1. LCC Ltd. did not perform at least one identity test on each shipment of each lot of high-risk components, including glycerin and propylene glycol, to detect diethylene glycol (DEG) or ethylene glycol (EG).

    21 CFR 211.84(d)(1)
  2. Its quality control unit did not effectively use its authority to approve or reject components.

    21 CFR 211.22(a)

What FDA wants

Respond in writing within 30 working days and provide DEG and EG test results from retained high-risk component lots within 30 calendar days. Also provide a risk assessment for unexpired products, a component testing plan, quality-unit remediation, and consider a qualified manufacturing consultant.

Who should pay attention

  • brands that buy finished OTC drugs from this contract manufacturer
  • US importers and distributors of OTC drug products
  • suppliers and buyers of glycerin or propylene glycol used in drugs

This is a summary. Read the original letter on fda.gov.

LCC Ltd.'s FDA history

  1. LCC Ltd.

    CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/Misbranded

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk